摘要
目的探讨吉非替尼治疗晚期肺腺癌的临床疗效。方法选取2019年10月至2020年12月间西安国际医学中心医院收治的144例晚期肺腺癌患者,根据治疗方法不同进行分组,其中,选择分子靶向药物吉非替尼治疗的72例患者纳入观察组,选择消癌平注射液静脉滴注治疗的72例患者纳入对照组。比较两组患者实体肿瘤的疗效、血浆纤维蛋白原(Fib)、血小板(PLT)水平、肿瘤无进展生存时间(PFS)、总生存时间(OS)、患者生活质量评分(QOL)及不良反应情况。结果观察组的疾病控制率和临床治疗总有效率分别为88.9%和69.4%,高于对照组的50.0%和36.1%,差异均有统计学意义(均P<0.05)。治疗前,两组患者Fib、PLT水平比较,差异无统计学意义(P>0.05)。治疗后,两组患者的Fib、PLT水平均升高,但观察组均低于对照组,差异均有统计学意义(均P<0.05)。观察组的PFS、OS和QOL评分均高于对照组,差异有统计学意义(均P<0.05)。观察组不良反应总发生率为8.3%,低于对照组的22.2%,差异有统计学意义(P<0.05)。结论晚期肺腺癌患者采用分子靶向药物吉非替尼治疗,可改善患者的生活质量,降低不良反应,延长生存时间,抑制Fib、PLT水平,加快康复速度,具有临床应用价值。
Objective To explore the efficacy of a molecular targeted agent gefitinib in patients with advanced lung adenocarcinoma.Methods A total of 144 patients with advanced lung adenocarcinoma were selected at Xi'an International Medical Center Hospital from October 2019 to December 2020.They were divided into two groups based on the therapies they received.Seventy-two patients receiving gefitinib were included an observation group and 72 patients receiving Xiaoaiping injection were included in a control group.The efficacy,fibrinogen(FIB),platelet(PLT),progression-free survival(PFS),overall survival(OS)and quality of life(QOL)score and adverse reactions were compared between the two groups.Results The disease control rate and the overall efficacy was 88.9%and 69.4%,respectively in the ob-servation group which was higher than 50.0%and 36.1%,respectively of the control group(all P<0.05).Before the treatment,there was no significant difference in FIB and PLT between the two groups(P>0.05).After the treatment,FIB and PLT levels increased in both groups and those levels were lower in the observation group than in the control group(all P<0.05).Scores of PFS,OS and QOL were higher in the observation group than in the control group(all P<0.05).The overall incidence of adverse reactions was 8.3%in the observation group,which was lower than 22.2%of the control group(P<0.05).Con-clusion For patients with advanced lung adenocarcinoma,molecular targeted agent gefitinib can signifi-cantly improve quality of life,reduce adverse reactions,prolong survival time,inhibit FIB and PLT levels,and accelerate the recovery,which has clinical application value.
作者
魏娜
曹军
WEI Na;CAO Jun(Second Ward of Cancer,Xi'an International Medical Center Hospital,Xi'an 710100,China;Depart-ment of Oncology,The Third Affiliated Hospital of Xi'an Medical College,Xi'an 710000,China)
出处
《中国肿瘤临床与康复》
2021年第10期1173-1176,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
